Patents Assigned to ALCRESTA THERAPEUTICS, INC.
  • Patent number: 11944596
    Abstract: Embodiments of the disclosure are drawn to an enteral feeding device for hydrolyzing triglycerides in a nutritional formula. The device may include a body housing a chamber, an inlet configured to fluidly couple with a source of nutritional formula, and an outlet configured to fluidly couple with an enteral feeding tube. The device may include a headspace and a plurality of particles contained within the chamber, wherein the lipase is covalently bonded to the plurality of particles. The device may include an inlet filter located between the inlet and the chamber, wherein the inlet filter contains a first plurality of openings, and an outlet filter located between the chamber and the outlet, wherein the outlet filter has a second plurality of openings smaller than the plurality of particles.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: April 2, 2024
    Assignee: Alcresta Therapeutics, Inc.
    Inventors: Robert Gallotto, Greta L. Loring, Kenneth Gary, Edward S. Park, David J. Brown, Willem Robert Klaas Schoevaart, Michiel Christian Alexander van Vliet
  • Publication number: 20240065943
    Abstract: Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monogiycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.
    Type: Application
    Filed: November 6, 2023
    Publication date: February 29, 2024
    Applicant: Alcresta Therapeutics, Inc.
    Inventors: Alexey L. MARGOLIN, Robert GALLOTTO, Bhami SHENOY
  • Patent number: 11911357
    Abstract: Embodiments of the disclosure are drawn to an enteral feeding device for hydrolyzing triglycerides in a nutritional formula. The device may include a body housing a chamber, an inlet configured to fluidly couple with a source of nutritional formula, and an outlet configured to fluidly couple with an enteral feeding tube. The device may include a headspace and a plurality of particles contained within the chamber, wherein the lipase is covalently bonded to the plurality of particles. The device may include an inlet filter located between the inlet and the chamber, wherein the inlet filter contains a first plurality of openings, and an outlet filter located between the chamber and the outlet, wherein the outlet filter has a second plurality of openings smaller than the plurality of particles.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: February 27, 2024
    Assignee: Alcresta Therapeutics, Inc.
    Inventors: Robert Gallotto, Greta L. Loring, Kenneth Gary, Edward S. Park, David J. Brown, Willem Robert Klaas Schoevaart, Michiel Christian Alexander van Vliet
  • Patent number: 11872191
    Abstract: Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monoglycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: January 16, 2024
    Assignee: Alcresta Therapeutics, Inc.
    Inventors: Alexey L. Margolin, Robert Gallotto, Bhami Shenoy
  • Publication number: 20230014170
    Abstract: Exemplary embodiments of the disclosure may be drawn to ingestible delivery devices. An ingestible delivery device may include a first compartment and a second compartment. A lipase may be contained within the first compartment, and a fat may be contained within the second compartment. The first compartment may be sealed from the second compartment prior to exposure to a trigger, preventing the lipase and the fat from contacting each other, and at least one of the first compartment or the second compartment may at least partially rupture upon exposure to the trigger, allowing the lipase and the fat to contact each other.
    Type: Application
    Filed: September 20, 2022
    Publication date: January 19, 2023
    Applicant: Alcresta Therapeutics, Inc.
    Inventors: Eric First, David Widom
  • Patent number: 11478431
    Abstract: Exemplary embodiments of the disclosure may be drawn to ingestible delivery devices. An ingestible delivery device may include a first compartment and a second compartment. A lipase may be contained within the first compartment, and a fat may be contained within the second compartment. The first compartment may be sealed from the second compartment prior to exposure to a trigger, preventing the lipase and the fat from contacting each other, and at least one of the first compartment or the second compartment may at least partially rupture upon exposure to the trigger, allowing the lipase and the fat to contact each other.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: October 25, 2022
    Assignee: Alcresta Therapeutics, Inc.
    Inventors: Eric First, David Widom
  • Publication number: 20220331208
    Abstract: Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monoglycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.
    Type: Application
    Filed: June 29, 2022
    Publication date: October 20, 2022
    Applicant: Alcresta Therapeutics, Inc
    Inventors: Alexey L. MARGOLIN, Robert GALLOTTO, Bhami SHENOY
  • Publication number: 20220331206
    Abstract: Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monoglycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.
    Type: Application
    Filed: June 29, 2022
    Publication date: October 20, 2022
    Applicant: Alcresta Therapeutics, Inc.
    Inventors: Alexey L. MARGOLIN, Robert GALLOTTO, Bhami SHENOY
  • Publication number: 20220331207
    Abstract: Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monoglycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.
    Type: Application
    Filed: June 29, 2022
    Publication date: October 20, 2022
    Applicant: Alcresta Therapeutics, Inc.
    Inventors: Alexey L. MARGOLIN, Robert GALLOTTO, Bhami SHENOY
  • Publication number: 20220264926
    Abstract: Exemplary embodiments of the disclosure may be drawn to a device having an inlet and a chamber. Immobilized lipase, immobilized protease, and immobilized amylase may be contained within the chamber. The device may also include an outlet, wherein a flow path extends from the inlet, through the chamber, and to the outlet.
    Type: Application
    Filed: March 1, 2022
    Publication date: August 25, 2022
    Applicant: Alcresta Therapeutics, Inc.
    Inventors: Eric FIRST, David BROWN, Albert Archie STONE
  • Patent number: 11291236
    Abstract: Exemplary embodiments of the disclosure may be drawn to a device having an inlet and a chamber. Immobilized lipase, immobilized protease, and immobilized amylase may be contained within the chamber. The device may also include an outlet, wherein a flow path extends from the inlet, through the chamber, and to the outlet.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: April 5, 2022
    Assignee: Alcresta Therapeutics, Inc.
    Inventors: Eric First, David Brown, Albert Archie Stone
  • Publication number: 20210283085
    Abstract: Embodiments of the disclosure are drawn to an enteral feeding device for hydrolyzing triglycerides in a nutritional formula. The device may include a body housing a chamber, an inlet configured to fluidly couple with a source of nutritional formula, and an outlet configured to fluidly couple with an enteral feeding tube. The device may include a headspace and a plurality of particles contained within the chamber, wherein the lipase is covalently bonded to the plurality of particles. The device may include an inlet filter located between the inlet and the chamber, wherein the inlet filter contains a first plurality of openings, and an outlet filter located between the chamber and the outlet, wherein the outlet filter has a second plurality of openings smaller than the plurality of particles.
    Type: Application
    Filed: May 27, 2021
    Publication date: September 16, 2021
    Applicant: Alcresta Therapeutics, Inc.
    Inventors: Robert GALLOTTO, Greta L. LORING, Kenneth GARY, Edward S. PARK, David J. BROWN, Willem Robert Klaas SCHOEVAART, Michiel Christian Alexander van VLIET
  • Publication number: 20210259924
    Abstract: Exemplary embodiments of the disclosure may be drawn to a device having a vessel configured to contain a source of lipids and a chamber fluidly connected to an outlet of the vessel. The chamber may contain immobilized lipase positioned within a flow path in the chamber along which the lipids flow when released from the vessel into the chamber. The device may also include an outlet through which the lipids flow after passing through the chamber.
    Type: Application
    Filed: May 11, 2021
    Publication date: August 26, 2021
    Applicant: Alcresta Therapeutics, Inc.
    Inventors: Eric FIRST, David Widom
  • Publication number: 20210212904
    Abstract: Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monogiycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.
    Type: Application
    Filed: March 24, 2021
    Publication date: July 15, 2021
    Applicant: Alcresta Therapeutics, Inc.
    Inventors: Alexey L. Margolin, Robert Gallotto, Bhami Shenoy
  • Patent number: 11045440
    Abstract: Embodiments of the disclosure are drawn to an enteral feeding device for hydrolyzing triglycerides in a nutritional formula. The device may include a body housing a chamber, an inlet configured to fluidly couple with a source of nutritional formula, and an outlet configured to fluidly couple with an enteral feeding tube. The device may include a headspace and a plurality of particles contained within the chamber, wherein the lipase is covalently bonded to the plurality of particles. The device may include an inlet filter located between the inlet and the chamber, wherein the inlet filter contains a first plurality of openings, and an outlet filter located between the chamber and the outlet, wherein the outlet filter has a second plurality of openings smaller than the plurality of particles.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: June 29, 2021
    Assignee: Alcresta Therapeutics, Inc.
    Inventors: Robert Gallotto, Greta L. Loring, Kenneth Gary, Edward S. Park, David J. Brown, Willem Robert Klaas Schoevaart, Michiel Christian Alexander van Vliet
  • Patent number: 11045396
    Abstract: Exemplary embodiments of the disclosure may be drawn to a device having a vessel configured to contain a source of lipids and a chamber fluidly connected to an outlet of the vessel. The chamber may contain immobilized lipase positioned within a flow path in the chamber along which the lipids flow when released from the vessel into the chamber. The device may also include an outlet through which the lipids flow after passing through the chamber.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: June 29, 2021
    Assignee: Alcresta Therapeutics, Inc.
    Inventors: Eric First, David Widom
  • Patent number: 10987280
    Abstract: Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monoglycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: April 27, 2021
    Assignee: Alcresta Therapeutics, Inc.
    Inventors: Alexey L. Margolin, Robert Gallotto, Bhami Shenoy
  • Patent number: 10828239
    Abstract: Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monogiycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: November 10, 2020
    Assignee: Alcresta Therapeutics, Inc.
    Inventors: Alexey L. Margolin, Robert Gallotto, Bhami Shenoy
  • Publication number: 20200306196
    Abstract: Exemplary embodiments of the disclosure may be drawn to ingestible delivery devices. An ingestible delivery device may include a first compartment and a second compartment. A lipase may be contained within the first compartment, and a fat may be contained within the second compartment. The first compartment may be sealed from the second compartment prior to exposure to a trigger, preventing the lipase and the fat from contacting each other, and at least one of the first compartment or the second compartment may at least partially rupture upon exposure to the trigger, allowing the lipase and the fat to contact each other.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Applicant: Alcresta Therapeutics, Inc.
    Inventors: Eric First, David Widom
  • Patent number: 10716761
    Abstract: Exemplary embodiments of the disclosure may be drawn to ingestible delivery devices. An ingestible delivery device may include a first compartment and a second compartment. A lipase may be contained within the first compartment, and a fat may be contained within the second compartment. The first compartment may be sealed from the second compartment prior to exposure to a trigger, preventing the lipase and the fat from contacting each other, and at least one of the first compartment or the second compartment may at least partially rupture upon exposure to the trigger, allowing the lipase and the fat to contact each other.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: July 21, 2020
    Assignee: Alcresta Therapeutics, Inc.
    Inventors: Eric First, David Widom